PRESS RELEASE published on 01/24/2024 at 09:02, 9 months 28 days ago Original-Research: VOQUZ Labs AG (von NuWays AG): BUY VOQUZ Labs AG has been upgraded from NuWays AG with a recommendation to buy. The company recently published strong 2023 order intake figures, indicating improved operations in the second half of the year. With a reassuring order intake and strong trading momentum, the company is expected to see sequential improvements in 2023 and return to double-digit top-line growth, positive EBITDA, and FCF generation in 2024. The compelling mid-term prospects and undemanding valuation indicate favorable investment potential. EBITDA VOQUZ Labs AG NuWays AG 2023 Order Intake Mid-term Prospects
Published on 11/21/2024 at 14:15, 20 minutes ago neurocare Group AG Welcomes Kevin Reeder as Chief Financial Officer
Published on 11/21/2024 at 14:00, 35 minutes ago Demotech, Inc. Assigns a Financial Stability Rating(R) of A, Exceptional, to Steadily Insurance Company
Published on 11/21/2024 at 14:00, 35 minutes ago Montara Raises $5.4M to Help Organizations Deliver Better Data Products Faster
Published on 11/21/2024 at 14:00, 35 minutes ago Tevir Capital LP Ltd. Updates Early Warning Reporting in Respect of VerticalScope Holdings Inc.
Published on 11/21/2024 at 14:16, 19 minutes ago EQS-Adhoc: LM PAY S.A. Announces Third Quarter 2024 Preliminary Results and Updated Guidance
Published on 11/21/2024 at 14:15, 20 minutes ago ZenaTech Signs Blue UAS and NDAA Compliant Supply Chain Partners to Sell to US Defense Branches and NATO Forces
Published on 11/21/2024 at 12:35, 2 hours ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 06:58, 7 hours 37 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 19 hours 15 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 50 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 50 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo